RECRUITING

Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension in Fetuses With Severe CDH

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Congenital diaphragmatic hernia (CDH) occurs when the diaphragm fails to fully fuse and leaves a portal through which abdominal structures can migrate into the thorax. In the more severe cases, the abdominal structures remain in the thoracic cavity and compromise the development of the lungs. Infants born with this defect have a decreased capacity for gas exchange; mortality rates after birth have been reported between 40-60%. Now that CDH can be accurately diagnosed by mid-gestation, a number of strategies have been developed to repair the hernia and promote lung tissue development. Fetal tracheal occlusion (FETO), using a fetoscopically delivered and removed balloon device, has been used to temporarily occlude the trachea and increase lung distension in CDH to allow the lungs to develop and has been shown to increase survival at birth. The role of FETO in the resolution of pulmonary hypertension in fetuses with severe left- and right- sided CDH remains unclear. Our recent observation that FETO is associated with a higher proportion of infants who resolve their pulmonary hypertension by the age of 1 year as compared with those who have not had FETO, is based on a retrospective cohort study, which, as with any such design, has some intrinsic limitations. Thus, a prospective cohort study that is appropriately powered to confirm or disprove this encouraging observation is needed. If our preliminary observation is confirmed, resolution of PH by the age of 1 year could be added to the benefits of the FETO procedure in severe left and right-sided CDH cases. The investigators will perform 40 FETO procedures on fetuses diagnosed prenatally with severe right- or left-sided CDH, and outcome data will be compared with that of a control group of severe right- or left-sided CDH who will not undergo the FETO procedure because of medical or social issues. Because the prevalence of left-sided CDH is higher than right-side CDH, the investigators will perform 25 FETO procedures in left sided CDH and 15 in right-sided CDH, and these outcomes will be compared to a cohort of 40 non FETO cases.

Official Title

A Prospective Study on the Role of Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension Among Fetuses With Severe Congenital Diaphragmatic Hernia

Quick Facts

Study Start:2019-08-09
Study Completion:2030-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03980717

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patient is a pregnant woman between 18 and 45 years of age
  2. * Singleton pregnancy
  3. * The fetuses will be 28+0/7 to 31+6/7 weeks of gestational age
  4. * Confirmed diagnosis of severe left- or right-sided CDH of the fetus: Observed/expected total lung volume equal to or less than 0.32 with more than 21% of liver herniated into the hemithorax. (Ideally calculated between 28+0/7 and 31+6/7 weeks' gestation.)
  5. * Normal fetal echocardiogram or echocardiogram with a minor anomaly (such a small VSD) that in the opinion of the pediatric cardiologist will not affect postnatal outcome
  6. * Normal fetal karyotype or microarray
  7. * The mother must be healthy enough to have surgery
  8. * Patient and father of the baby provide signed informed consent that details the maternal and fetal risks involved with the procedure
  9. * Patient willing to remain in Houston for the duration following balloon placement until delivery.
  1. * Contraindication to abdominal surgery, fetoscopic surgery, or general anesthesia
  2. * Allergy to latex
  3. * Allergy or previous adverse reaction to a study medication specified in this protocol
  4. * Preterm labor, preeclampsia, or uterine anomaly (e.g., large fibroid tumor) in the index pregnancy.
  5. * Fetal aneuploidy, known structural genomic variants, other major fetal anomalies that may impact the fetal/neonatal survival or known syndromic mutation
  6. * Suspicion of major recognized syndrome (e.g. Fryns syndrome) on ultrasound or MRI
  7. * Maternal BMI \>40
  8. * High risk for fetal hemophilia

Contacts and Locations

Study Contact

Michael Belfort, MD PhD
CONTACT
832-826-7375
belfort@bcm.edu
Rebecca M Johnson, BA
CONTACT
832-826-7451
rj2@bcm.edu

Principal Investigator

Michael Belfort, MD PhD
PRINCIPAL_INVESTIGATOR
Baylor College of Medicine - Texas Children's Hospital

Study Locations (Sites)

Texas Childrens Hospital
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: Michael A Belfort

  • Michael Belfort, MD PhD, PRINCIPAL_INVESTIGATOR, Baylor College of Medicine - Texas Children's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-08-09
Study Completion Date2030-12

Study Record Updates

Study Start Date2019-08-09
Study Completion Date2030-12

Terms related to this study

Keywords Provided by Researchers

  • Fetal Tracheal Occlusion
  • FETO plug-unplug
  • Goldvalve balloon
  • Severe Congenital Diaphragmatic Hernia
  • Goldbal balloon
  • FETO

Additional Relevant MeSH Terms

  • Congenital Diaphragmatic Hernia